Larazotide acetate 醋酸拉瑞唑来|cas:881851-50-9|西域试剂

Larazotide acetate 醋酸拉瑞唑来,98.71%

产品编号：Bellancom-106268A| CAS NO：881851-50-9| 分子式：C₃₄H₅₉N₉O₁₂| 分子量：785.89

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-106268A	￥700.00	杭州北京（现货）
Bellancom-106268A	￥1500.00	杭州北京（现货）
Bellancom-106268A	￥2400.00	杭州北京（现货）
Bellancom-106268A	￥5200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Larazotide acetate 醋酸拉瑞唑来

产品介绍

Larazotide acetate 是一种多肽，是具有口服活性的 zonulin 拮抗剂。Larazotide acetate 对水痘带状疱疹病毒 (VZV) 具有抗病毒活性，对 OKA 和 07-1 株系的 EC₅₀ 值分别为 44.14 和 59.06 μM。Larazotide acetate 可用于乳糜泻和感染的研究。

生物活性

Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC₅₀s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection.

体外研究

Larazotide acetate (1-100 μM; 5 d) affects Vero cell growth.
Larazotide acetate (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC₅₀s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively.
Larazotide acetate (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells.
Larazotide acetate (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	Vero cell line
Concentration:	1-100 μM
Incubation Time:	5 days
Result:	Inhibited Vero cell growth with an CC₅₀ value of 82.5 μM.

体内研究
(In Vivo)

Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HLA-HCD4/DQ8 double transgenic mice
Dosage:	250 μg
Administration:	Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:	Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.

体内研究

Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HLA-HCD4/DQ8 double transgenic mice
Dosage:	250 μg
Administration:	Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:	Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.

体内研究

Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HLA-HCD4/DQ8 double transgenic mice
Dosage:	250 μg
Administration:	Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:	Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.

性状

Solid

溶解性数据

In Vitro:

H₂O : 16.67 mg/mL (21.21 mM; Need ultrasonic)

DMSO : 3.2 mg/mL (4.07 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2724 mL	6.3622 mL	12.7244 mL
5 mM	0.2545 mL	1.2724 mL	2.5449 mL
10 mM	0.1272 mL	0.6362 mL	1.2724 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶